A Barberan-Garcia1, M Ubre2, N Pascual-Argente3, R Risco2, J Faner4, J Balust2, A M Lacy5, J Puig-Junoy3, J Roca6, G Martinez-Palli7. 1. Respiratory Medicine Department, Hospital Clínic de Barcelona, Barcelona, Spain; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; Biomedical Networking Research Centre on Respiratory Diseases (CIBERES), Madrid, Spain. Electronic address: anbarber@clinic.cat. 2. Anaesthesiology Department, Hospital Clínic de Barcelona, Barcelona, Spain. 3. UPF Barcelona School of Management, Spain; Economics and Business Department, Centre for Research in Health and Economics (CRES-UPF), Pompeu Fabra University, Barcelona, Spain. 4. Economics and Business Department, Centre for Research in Health and Economics (CRES-UPF), Pompeu Fabra University, Barcelona, Spain; Economics Department, Metabolic and Digestive Diseases Institute, Spain. 5. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; Gastrointestinal Surgery Department, Hospital Clínic de Barcelona, Barcelona, Spain; Biomedical Networking Research Centre on Hepatic Diseases (CIBEREHD), Madrid, Spain. 6. Respiratory Medicine Department, Hospital Clínic de Barcelona, Barcelona, Spain; August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; Biomedical Networking Research Centre on Respiratory Diseases (CIBERES), Madrid, Spain. 7. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; Anaesthesiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: Prehabilitation may reduce postoperative complications, but sustainability of its health benefits and impact on costs needs further evaluation. Our aim was to assess the midterm clinical impact and costs from a hospital perspective of an endurance-exercise-training-based prehabilitation programme in high-risk patients undergoing major digestive surgery. METHODS: A cost-consequence analysis was performed using secondary data from a randomised, blinded clinical trial. The main outcomes assessed were (i) 30-day hospital readmissions, (ii) endurance time (ET) during an exercise testing, and (iii) physical activity by the Yale Physical Activity Survey (YPAS). Healthcare use for the cost analysis included costs of the prehabilitation programme, hospitalisation, and 30-day emergency room visits and hospital readmissions. RESULTS: We included 125 patients in an intention-to-treat analysis. Prehabilitation showed a protective effect for 30-day hospital readmissions (relative risk: 6.4; 95% confidence interval [CI]: 1.4-30.0). Prehabilitation-induced enhancement of ET and YPAS remained statistically significant between groups at the end of the 3 and 6 month follow-up periods, respectively (ΔET 205 [151] s; P=0.048) (ΔYPAS 7 [2]; P=0.016). The mean cost of the programme was €389 per patient and did not increment the total costs of the surgical process (€812; CI: 95% -878 - 2642; P=0.365). CONCLUSIONS: Prehabilitation may result in health value generation. Moreover, it appears to be a protective intervention for 30-day hospital readmissions, and its effects on aerobic capacity and physical activity may show sustainability at midterm. CLINICAL TRIAL REGISTRATION: NCT02024776.
RCT Entities:
BACKGROUND: Prehabilitation may reduce postoperative complications, but sustainability of its health benefits and impact on costs needs further evaluation. Our aim was to assess the midterm clinical impact and costs from a hospital perspective of an endurance-exercise-training-based prehabilitation programme in high-risk patients undergoing major digestive surgery. METHODS: A cost-consequence analysis was performed using secondary data from a randomised, blinded clinical trial. The main outcomes assessed were (i) 30-day hospital readmissions, (ii) endurance time (ET) during an exercise testing, and (iii) physical activity by the Yale Physical Activity Survey (YPAS). Healthcare use for the cost analysis included costs of the prehabilitation programme, hospitalisation, and 30-day emergency room visits and hospital readmissions. RESULTS: We included 125 patients in an intention-to-treat analysis. Prehabilitation showed a protective effect for 30-day hospital readmissions (relative risk: 6.4; 95% confidence interval [CI]: 1.4-30.0). Prehabilitation-induced enhancement of ET and YPAS remained statistically significant between groups at the end of the 3 and 6 month follow-up periods, respectively (ΔET 205 [151] s; P=0.048) (ΔYPAS 7 [2]; P=0.016). The mean cost of the programme was €389 per patient and did not increment the total costs of the surgical process (€812; CI: 95% -878 - 2642; P=0.365). CONCLUSIONS: Prehabilitation may result in health value generation. Moreover, it appears to be a protective intervention for 30-day hospital readmissions, and its effects on aerobic capacity and physical activity may show sustainability at midterm. CLINICAL TRIAL REGISTRATION: NCT02024776.
Authors: Elizabeth Shelton; Nicolas B Barreto; Serena Bidwell; Margaret Folk-Tolbert; Andrew Shelton; Amber W Trickey; Cindy J Kin Journal: J Gastrointest Surg Date: 2021-10-19 Impact factor: 3.452
Authors: Daniel Santa Mina; Daniel Sellers; Darren Au; Shabbir M H Alibhai; Hance Clarke; Brian H Cuthbertson; Gail Darling; Alaa El Danab; Anand Govindarajan; Karim Ladha; Andrew G Matthew; Stuart McCluskey; Karen A Ng; Fayez Quereshy; Keyvan Karkouti; Ian M Randall Journal: Front Oncol Date: 2021-03-10 Impact factor: 6.244
Authors: Thea C Heil; Elisabeth J M Driessen; Tanja E Argillander; René J F Melis; Huub A A M Maas; Marcel G M Olde Rikkert; Johannes H W de Wilt; Barbara C van Munster; Marieke Perry Journal: Support Care Cancer Date: 2022-05-25 Impact factor: 3.359
Authors: Daniel Santa Mina; Stefanus J van Rooijen; Enrico M Minnella; Shabbir M H Alibhai; Priya Brahmbhatt; Susanne O Dalton; Chelsia Gillis; Michael P W Grocott; Doris Howell; Ian M Randall; Catherine M Sabiston; Julie K Silver; Gerrit Slooter; Malcolm West; Sandy Jack; Franco Carli Journal: Front Oncol Date: 2021-01-11 Impact factor: 6.244
Authors: Laura van Wijk; Lizzel van der Snee; Carlijn I Buis; Judith E K R Hentzen; Marjolein E Haveman; Joost M Klaase Journal: Perioper Med (Lond) Date: 2021-02-17
Authors: Pishoy Gouda; Xiaoming Wang; Erik Youngson; Michael McGillion; Mamas A Mamas; Michelle M Graham Journal: PLoS One Date: 2022-01-19 Impact factor: 3.240